Zymeworks (ZYME) News Today → How this is some devastating news (From WealthPress) (Ad) Free ZYME Stock Alerts $9.12 -0.26 (-2.77%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 4:20 PM | businesswire.comKirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME)May 9, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)May 9, 2024 | americanbankingnews.comZymeworks (NYSE:ZYME) Stock Rating Reaffirmed by HC WainwrightMay 8, 2024 | markets.businessinsider.comHold Rating on Zymeworks: Balancing Potential Rewards and Valuation RisksMay 7, 2024 | benzinga.comZymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)May 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEMay 3, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Price Target Lowered to $16.00 at CitigroupCitigroup dropped their price target on Zymeworks from $17.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday.May 3, 2024 | markets.businessinsider.comOptimistic Buy Rating for Zymeworks: Anticipated Approvals and Strong Pipeline PotentialMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zymeworks on Strong Pipeline and Upcoming CatalystsMay 3, 2024 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comZymeworks Inc (ZYME) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...April 30, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 19, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Shares Up 3.5%Zymeworks (NYSE:ZYME) Trading Up 3.5%April 18, 2024 | seekingalpha.comBuy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising DataApril 16, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud AllegationsApril 12, 2024 | markets.businessinsider.comMaintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory HurdlesApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 11, 2024 | globenewswire.comZymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024April 9, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Trading Down 2.6%Zymeworks (NYSE:ZYME) Shares Down 2.6%April 8, 2024 | globenewswire.comZymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual MeetingApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 4, 2024 | morningstar.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)April 2, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYMEApril 1, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Stock Price Down 6.7%Zymeworks (NYSE:ZYME) Stock Price Down 6.7%March 29, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Purchased by Wellington Management Group LLPWellington Management Group LLP grew its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 177.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 156,682 shares of the company's stock after acquiMarch 28, 2024 | finanznachrichten.deZymeworks Inc.: Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of DirectorsMarch 28, 2024 | globenewswire.comZymeworks Announces Appointment of Dr. Neil Gallagher to its Board of DirectorsMarch 27, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesMarch 13, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)March 13, 2024 | marketbeat.comAQR Capital Management LLC Has $5.07 Million Stock Holdings in Zymeworks Inc. (NYSE:ZYME)AQR Capital Management LLC lifted its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 70.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 799,679 shares of the company's stock after purchasing an additiMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of ZanidatamabMarch 11, 2024 | markets.businessinsider.comHold Rating on Zymeworks Amidst Pipeline Adjustments and Clinical Validation AwaitedMarch 8, 2024 | investorplace.comNext-Gen Winners: 7 Tech Stocks Set to Dominate the DecadeMarch 7, 2024 | finanznachrichten.deZymeworks Inc.: Zymeworks Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | finance.yahoo.comZymeworks Inc. (NYSE:ZYME) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comZymeworks Inc (ZYME) Reports Financial Results for Q4 and Full Year 2023March 7, 2024 | investorplace.comZYME Stock Earnings: Zymeworks Beats EPS, Beats Revenue for Q4 2023March 6, 2024 | seekingalpha.comZymeworks Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 6, 2024 | msn.comZymeworks Q4 2023 Earnings PreviewMarch 6, 2024 | globenewswire.comZymeworks Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 6, 2024 | marketbeat.comRubric Capital Management LP Increases Holdings in Zymeworks Inc. (NYSE:ZYME)Rubric Capital Management LP grew its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 12.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 2,651,394 shares of the company's stock after acquiring an additional 293,817 shares during tMarch 5, 2024 | globenewswire.comZymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual MeetingMarch 5, 2024 | ca.finance.yahoo.comZYME Apr 2024 7.500 callMarch 5, 2024 | ca.finance.yahoo.comZYME Oct 2024 15.000 callMarch 5, 2024 | finance.yahoo.comZYME Mar 2024 20.000 callMarch 5, 2024 | seekingalpha.comZymeworks: A Strong Buy Amidst Zanidatamab's Promising DevelopmentsMarch 4, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Deutsche Bank AGDeutsche Bank AG reduced its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 81.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 114,853 shares of the company's stock after selling 490,281 shares during the perFebruary 27, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Reaches New 12-Month High at $12.71Zymeworks (NYSE:ZYME) Sets New 1-Year High at $12.71 Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. ZYME Media Mentions By Week ZYME Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYME News Sentiment▼0.130.42▲Average Medical News Sentiment ZYME News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYME Articles This Week▼12▲ZYME Articles Average Week Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SVRA News SLN News LYEL News MLYS News PHAR News AVBP News ORIC News PHAT News STOK News CALT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ZYME) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressMost important medical advance in 100 yearsThe Oxford ClubUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingNext President (Not Trump. Not Biden.)The Freeport Society41 banks launch ‘crypto dollar’Stansberry ResearchWhat’s Really Next for America…Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
